The TME of tumor cells treated with the combination of anti-IL-1β and anti-PD-1 therapies showed a statistically higher percentage of CD8+ T cells, indicating a reversal of the immunosuppressive effects of IL-1β [82]. This evidence concerns the gene PDCD1 and neoplasm.